TKV and htTKV at baseline, 1-year follow-up (primary short-term outcome), and 3-year follow-up in the study group as a whole (overall) and in the 2 subgroups with CKD stage 3b and 4 considered separately, according to treatment with octreotide-LAR or placebo.
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://figshare.com/articles/dataset/TKV_and_htTKV_at_baseline_1-year_follow-up_primary_short-term_outcome_and_3-year_follow-up_in_the_study_group_as_a_whole_overall_and_in_the_2_subgroups_with_CKD_stage_3b_and_4_considered_separately_according_to_treatment_with_octreotide-LAR_or_placebo_/7959647
下载链接
链接失效反馈官方服务：
资源简介：
TKV and htTKV at baseline, 1-year follow-up (primary short-term outcome), and 3-year follow-up in the study group as a whole (overall) and in the 2 subgroups with CKD stage 3b and 4 considered separately, according to treatment with octreotide-LAR or placebo.
创建时间：
2019-04-05
